Connaught TriPedia DTaP vaccine recommended for infants two months and older by FDA cmte..
Executive Summary
CONNAUGHT TRIPEDIA DTaP INFANT USE POSTMARKETING SAFETY STUDIES recommended by FDA's Vaccines & Related Biological Products Advisory Committee Jan. 29 in conjunction with a favorable review of efficacy data. The committee agreed that Phase III efficacy studies and immunogenicity data are adequate to support the conclusion that the vaccine is effective when administered to infants as a primary series at two, four and six months of age.